Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Potential Ad Therapeutic Equipment Supplied In Usa
96 equipment items found
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for ...
by:Vir Biotechnology, Inc. based inSan Francisco, CALIFORNIA (USA)
We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
by:Neoclease based inBoston, MASSACHUSETTS (USA)
Neoclease is pioneering the future of precision medicine through advanced technology in synthetic biology and generative AI. By developing synthetic nucleases, the company enhances gene editing processes to achieve unprecedented specificity and efficacy. These enzymes are meticulously crafted using proprietary algorithms powered by state-of-the-art GPT neural networks, which are capable of ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor ...
Manufactured by:Impel Pharmaceuticals Inc. based inSeattle, WASHINGTON (USA)
Impel Pharmaceuticals has developed a proprietary drug delivery technology system that targets the vascular-rich upper nasal space,1 with multiple clinical trials suggesting rapid absorption and consistent drug bioavailability with ease of use in mind for a patient, provider or caregiver. Impel Pharmaceuticals proprietary Precision Olfactory Delivery (POD®) technology has the potential to ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
by:Reaction Biology Corp. based inMalvern, PENNSYLVANIA (USA)
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone methyltransferase domain and has been found to play a role in the regulation of Hox gene expression. Although the ASH1L SET domain has been shown in vitro to ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
Manufactured by:Sangamo Therapeutics based inBrisbane, CALIFORNIA (USA)
Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. The RORA protein plays an important role in lipid metabolism and demonstrates ...
Manufactured by:Sage Therapeutics based inCambridge, MASSACHUSETTS (USA)
The human brain is a network of billions of nerve cells, connected in complex electrical circuits to communicate. Brain health and function depend on these circuits. The flow of information among these circuits is managed by neural regulatory pathways including the GABA and NMDA receptors ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein that is present on the surface of other cells, including cancer cells. Upon recognition of the target cell via the CAR, the CAR-T cell kills the ...